{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,23]],"date-time":"2026-08-23T16:47:58Z","timestamp":1787503678821,"version":"build-2736575974"},"reference-count":38,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,4,27]],"date-time":"2026-04-27T00:00:00Z","timestamp":1777248000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","esmoopen.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["ESMO Open"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1016\/j.esmoop.2026.107775","type":"journal-article","created":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T19:10:41Z","timestamp":1781118641000},"page":"107775","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Anti-EGFR-based maintenance versus stop and go in patients with left-sided, non-MSI-H, RAS\/BRAF-wt metastatic colorectal cancer: individual patient data pooled analysis"],"prefix":"10.1016","volume":"11","author":[{"given":"A.","family":"Raimondi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1762-1375","authenticated-orcid":false,"given":"G.","family":"Tin\u00e8","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V.","family":"Boige","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2107-1177","authenticated-orcid":false,"given":"A.","family":"De Stefano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5470-4973","authenticated-orcid":false,"given":"A.","family":"Ballhausen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Gourgou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Giuliani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1041-0137","authenticated-orcid":false,"given":"A.","family":"Stahler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Randon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5596-469X","authenticated-orcid":false,"given":"M.","family":"Prisciandaro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3813-6339","authenticated-orcid":false,"given":"P.","family":"Manca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Ambrosini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-6690-2101","authenticated-orcid":false,"given":"R.","family":"Fazio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Mohamed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Gronchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8317-0907","authenticated-orcid":false,"given":"G.","family":"Santabarbara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-6757-293X","authenticated-orcid":false,"given":"E.","family":"Brument","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3922-3450","authenticated-orcid":false,"given":"A.H.S.","family":"Alig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Miceli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8284-3743","authenticated-orcid":false,"given":"O.","family":"Bouche","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6853-0599","authenticated-orcid":false,"given":"D.P.","family":"Modest","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Avallone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8530-8420","authenticated-orcid":false,"given":"F.","family":"Pietrantonio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.esmoop.2026.107775_bib1","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.annonc.2022.10.003","article-title":"Metastatic colorectal cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up","volume":"34","author":"Cervantes","year":"2023","journal-title":"Ann Oncol"},{"key":"10.1016\/j.esmoop.2026.107775_bib2","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1093\/annonc\/mdx175","article-title":"Prognostic and predictive value of primary tumour side in patients with RAS wild-type metastatic colorectal cancer treated with chemotherapy and EGFR directed antibodies in six randomized trials","volume":"28","author":"Arnold","year":"2017","journal-title":"Ann Oncol"},{"key":"10.1016\/j.esmoop.2026.107775_bib3","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2024.103677","article-title":"Impact of primary tumor sidedness and sex on prognosis and anti-epidermal growth factor receptor antibody efficacy in BRAF-mutant metastatic colorectal cancer: a pooled analysis of AIO studies FIRE-1, CIOX, FIRE-3, XELAVIRI, and VOLFI","volume":"9","author":"Alig","year":"2024","journal-title":"ESMO Open"},{"key":"10.1016\/j.esmoop.2026.107775_bib4","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1200\/JCO.2014.59.4812","article-title":"Fluorouracil, leucovorin, and irinotecan plus cetuximab treatment and RAS mutations in colorectal cancer","volume":"33","author":"Van Cutsem","year":"2015","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.esmoop.2026.107775_bib5","doi-asserted-by":"crossref","first-page":"3009","DOI":"10.1093\/annonc\/mdx546","article-title":"Negative hyper-selection of metastatic colorectal cancer patients for anti-EGFR monoclonal antibodies: the PRESSING case-control study","volume":"28","author":"Cremolini","year":"2017","journal-title":"Ann Oncol"},{"key":"10.1016\/j.esmoop.2026.107775_bib6","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.ejca.2023.02.006","article-title":"Primary tumour side as a driver for treatment choice in RAS wild-type metastatic colorectal cancer patients: a systematic review and pooled analysis of randomised trials","volume":"184","author":"Rossini","year":"2023","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.esmoop.2026.107775_bib7","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.1158\/1078-0432.CCR-23-3023","article-title":"Negative hyperselection of resistance mutations for panitumumab maintenance in RAS wild-type metastatic colorectal cancer (PanaMa phase II trial, AIO KRK 0212)","volume":"30","author":"Stahler","year":"2024","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.esmoop.2026.107775_bib8","article-title":"Negative ultraselection of patients with RAS\/BRAF wild-type, microsatellite-stable metastatic colorectal cancer receiving anti-EGFR-based therapy","volume":"6","author":"Randon","year":"2022","journal-title":"JCO Precis Oncol"},{"key":"10.1016\/j.esmoop.2026.107775_bib9","doi-asserted-by":"crossref","first-page":"3099","DOI":"10.1200\/JCO.19.01254","article-title":"Negative hyperselection of patients with RAS and BRAF wild-type metastatic colorectal cancer who received panitumumab-based maintenance therapy","volume":"37","author":"Morano","year":"2019","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.esmoop.2026.107775_bib10","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1001\/jama.2023.4428","article-title":"Panitumumab vs bevacizumab added to standard first-line chemotherapy and overall survival among patients with RAS wild-type, left-sided metastatic colorectal cancer: a randomized clinical trial","volume":"329","author":"Watanabe","year":"2023","journal-title":"JAMA"},{"key":"10.1016\/j.esmoop.2026.107775_bib11","doi-asserted-by":"crossref","first-page":"1278","DOI":"10.1200\/JCO.23.01021","article-title":"Fluorouracil, leucovorin, and irinotecan plus cetuximab versus cetuximab as maintenance therapy in first-line therapy for RAS and BRAF wild-type metastatic colorectal cancer: phase III ERMES study","volume":"42","author":"Pinto","year":"2024","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.esmoop.2026.107775_bib12","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejca.2023.112945","article-title":"Optimal maintenance strategy following FOLFOX plus anti-EGFR induction therapy in patients with RAS wild type metastatic colorectal cancer: an individual patient data pooled analysis of randomised clinical trials","volume":"190","author":"Raimondi","year":"2023","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.esmoop.2026.107775_bib13","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1200\/JCO.21.01332","article-title":"Panitumumab plus fluorouracil and folinic acid versus fluorouracil and folinic acid alone as maintenance therapy in RAS wild-type metastatic colorectal cancer: the randomized PANAMA trial (AIO KRK 0212)","volume":"40","author":"Modest","year":"2022","journal-title":"J Clin Oncol"},{"issue":"9","key":"10.1016\/j.esmoop.2026.107775_bib14","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.1001\/jamaoncol.2019.1467","article-title":"Maintenance therapy with panitumumab alone vs panitumumab plus fluorouracil-leucovorin in patients with RAS wild-type metastatic colorectal cancer: a phase 2 randomized clinical trial","volume":"5","author":"Pietrantonio","year":"2019","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.esmoop.2026.107775_bib15","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2023.33533","article-title":"Maintenance therapy with cetuximab after FOLFIRI plus cetuximab for RAS wild-type metastatic colorectal cancer: a phase 2 randomized clinical trial","volume":"6","author":"Boige","year":"2023","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.esmoop.2026.107775_bib16","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1016\/S1470-2045(14)70106-8","article-title":"Intermittent chemotherapy plus either intermittent or continuous cetuximab for first-line treatment of patients with KRAS wild-type advanced colorectal cancer (COIN-B): a randomised phase 2 trial","volume":"15","author":"Wasan","year":"2014","journal-title":"Lancet Oncol"},{"issue":"7","key":"10.1016\/j.esmoop.2026.107775_bib17","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1200\/JCO.24.00979","article-title":"Intermittent or continuous panitumumab plus fluorouracil, leucovorin, and irinotecan for first-line treatment of RAS and BRAF wild-type metastatic colorectal cancer: the IMPROVE trial","volume":"43","author":"Avallone","year":"2025","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.esmoop.2026.107775_bib18","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1016\/j.ejca.2020.04.048","article-title":"Health-related quality of life in patients with RAS wild-type metastatic colorectal cancer treated with panitumumab-based first-line treatment strategy: a pre-specified secondary analysis of the Valentino study","volume":"135","author":"Raimondi","year":"2020","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.esmoop.2026.107775_bib19","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejca.2023.112955","article-title":"Health-related quality of life in patients with RAS wild-type metastatic colorectal cancer treated with fluorouracil and folinic acid with or without panitumumab as maintenance therapy: a prespecified secondary analysis of the PanaMa (AIO KRK 0212) trial","volume":"190","author":"Ballhausen","year":"2023","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.esmoop.2026.107775_bib20","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2024.103628","volume":"9","author":"Ballhausen","year":"2024","journal-title":"ESMO Open"},{"key":"10.1016\/j.esmoop.2026.107775_bib21","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1016\/j.ctrv.2011.09.004","article-title":"Recommendations on management of EGFR inhibitor-induced skin toxicity: a systematic review","volume":"38","author":"Baas","year":"2012","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.esmoop.2026.107775_bib22","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1093\/annonc\/mdi279","article-title":"Clinical signs, pathophysiology and management of skin toxicity during therapy with epidermal growth factor receptor inhibitors","volume":"16","author":"Segaert","year":"2005","journal-title":"Ann Oncol"},{"key":"10.1016\/j.esmoop.2026.107775_bib23","article-title":"Panitumumab plus 5-fluorouracil and folinic acid or 5-fluorouracil and folinic acid alone as maintenance therapy in RAS wild-type metastatic colorectal cancer (PanaMa, AIO KRK 0212): final efficacy analysis of a randomised, open-label, phase 2 trial","volume":"79","author":"Stahler","year":"2024","journal-title":"EClinicalMedicine"},{"issue":"28","key":"10.1016\/j.esmoop.2026.107775_bib24","doi-asserted-by":"crossref","first-page":"3661","DOI":"10.1002\/sim.6607","article-title":"Moving towards best practice when using inverse probability of treatment weighting (IPTW) using the propensity score to estimate causal treatment effects in observational studies","volume":"34","author":"Austin","year":"2015","journal-title":"Stat Med"},{"issue":"3","key":"10.1016\/j.esmoop.2026.107775_bib25","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1007\/BF00985760","article-title":"Frailty models for survival data","volume":"1","author":"Hougaard","year":"1995","journal-title":"Lifetime Data Anal"},{"issue":"10449","key":"10.1016\/j.esmoop.2026.107775_bib26","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1016\/S0140-6736(24)00360-X","article-title":"Colorectal cancer","volume":"404","author":"Eng","year":"2024","journal-title":"Lancet"},{"key":"10.1016\/j.esmoop.2026.107775_bib27","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1200\/JCO.2021.39.3_suppl.85","article-title":"PARADIGM study: a multicenter, randomized, phase III study of mFOLFOX6 plus panitumumab or bevacizumab as first-line treatment in patients with RAS (KRAS\/NRAS) wild-type metastatic colorectal cancer","volume":"39","author":"Yoshino","year":"2021","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.esmoop.2026.107775_bib28","doi-asserted-by":"crossref","first-page":"3508","DOI":"10.1200\/JCO.2023.41.16_suppl.3508","article-title":"Efficacy of panitumumab in patients with left-sided disease, MSS\/MSI-L, and RAS\/BRAF WT: a biomarker study of the phase III PARADIGM trial","volume":"41","author":"Yamazaki","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.esmoop.2026.107775_bib29","first-page":"34","article-title":"Dermatologic toxicities associated with EGFR inhibitors: the clinical psychologist\u2019s perspective. Impact on health-related quality of life and implications for clinical management of psychological sequelae","volume":"21","author":"Wagner","year":"2007","journal-title":"Oncology (Williston Park)"},{"key":"10.1016\/j.esmoop.2026.107775_bib30","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejca.2023.05.001","article-title":"Adverse events during first-line treatments for mCRC: the Toxicity over Time (ToxT) analysis of three randomised trials","volume":"189","author":"Boccaccino","year":"2023","journal-title":"Eur J Cancer"},{"issue":"5","key":"10.1016\/j.esmoop.2026.107775_bib31","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1016\/S1470-2045(16)00038-3","article-title":"Longitudinal adverse event assessment in oncology clinical trials: the Toxicity over Time (ToxT) analysis of Alliance trials NCCTG N9741 and 979254","volume":"17","author":"Thanarajasingam","year":"2016","journal-title":"Lancet Oncol"},{"issue":"15 suppl","key":"10.1016\/j.esmoop.2026.107775_bib32","doi-asserted-by":"crossref","first-page":"3610","DOI":"10.1200\/JCO.2021.39.15_suppl.3610","article-title":"Evaluating longitudinal toxicity of cetuximab in patients with metastatic colorectal cancer (mCRC): a pooled analysis from 1,302 patients in the ARCAD database","volume":"39","author":"Lopes","year":"2021","journal-title":"J Clin Oncol"},{"issue":"14","key":"10.1016\/j.esmoop.2026.107775_bib33","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1200\/JCO.18.01798","article-title":"Mutational analysis of patients with colorectal cancer in CALGB\/SWOG 80405 identifies new roles of microsatellite instability and tumor mutational burden for patient outcome","volume":"37","author":"Innocenti","year":"2019","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.esmoop.2026.107775_bib34","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1038\/nm0715-827b","article-title":"Clonal evolution and resistance to EGFR blockade in the blood of colorectal cancer patients","volume":"21","author":"Siravegna","year":"2015","journal-title":"Nat Med"},{"key":"10.1016\/j.esmoop.2026.107775_bib35","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1200\/JCO.22.00365","article-title":"Acquired genomic alterations on first-line chemotherapy with cetuximab in advanced colorectal cancer: circulating tumor DNA analysis of the CALGB\/SWOG-80405 trial (alliance)","volume":"41","author":"Raghav","year":"2023","journal-title":"J Clin Oncol"},{"issue":"4","key":"10.1016\/j.esmoop.2026.107775_bib36","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2024.5635","article-title":"Anti-EGFR rechallenge in patients with refractory ctDNA RAS\/BRAF wt metastatic colorectal cancer: a nonrandomized controlled trial","volume":"7","author":"Ciardiello","year":"2024","journal-title":"JAMA Netw Open"},{"issue":"17 suppl","key":"10.1016\/j.esmoop.2026.107775_bib37","article-title":"Panitumumab retreatment followed by regorafenib versus the reverse sequence in chemorefractory metastatic colorectal cancer patients with RAS and BRAF wild-type circulating tumor DNA (ctDNA): results of the phase II randomized PARERE trial by GONO","volume":"43","author":"Cremolini","year":"2025","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.esmoop.2026.107775_bib38","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1038\/s41591-023-02791-w","article-title":"Baseline ctDNA gene alterations as a biomarker of survival after panitumumab and chemotherapy in metastatic colorectal cancer","volume":"30","author":"Shitara","year":"2024","journal-title":"Nat Med"}],"container-title":["ESMO Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2059702926017175?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2059702926017175?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T02:33:56Z","timestamp":1785897236000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2059702926017175"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":38,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["S2059702926017175"],"URL":"https:\/\/doi.org\/10.1016\/j.esmoop.2026.107775","relation":{},"ISSN":["2059-7029"],"issn-type":[{"value":"2059-7029","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Anti-EGFR-based maintenance versus stop and go in patients with left-sided, non-MSI-H, RAS\/BRAF-wt metastatic colorectal cancer: individual patient data pooled analysis","name":"articletitle","label":"Article Title"},{"value":"ESMO Open","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.esmoop.2026.107775","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Ltd on behalf of European Society for Medical Oncology.","name":"copyright","label":"Copyright"}],"article-number":"107775"}}